{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T17:22:38Z","timestamp":1763400158941,"version":"3.44.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T00:00:00Z","timestamp":1685318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Sumitomo Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.jad.2023.05.065","type":"journal-article","created":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T20:49:45Z","timestamp":1685134185000},"page":"150-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials"],"prefix":"10.1016","volume":"337","author":[{"given":"Masaki","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiya","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadafumi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.05.065_bb0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00213-002-1147-6","article-title":"Citalopram dose-response revisited using an alternative psychometric approach to evaluate clinical effects of four fixed citalopram doses compared to placebo in patients with major depression","volume":"163","author":"Bech","year":"2002","journal-title":"Psychopharmacology (Berlin)"},{"key":"10.1016\/j.jad.2023.05.065_bb0010","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/WNF.0b013e318237709a","article-title":"A randomized open comparison of long-acting injectable risperidone and treatment as usual for prevention of relapse, rehospitalization, and urgent care referral in community-treated patients with rapid cycling bipolar disorder","volume":"34","author":"Bobo","year":"2011","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jad.2023.05.065_bb0015","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.euroneuro.2017.06.013","article-title":"Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder","volume":"27","author":"Calabrese","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.05.065_bb0020","doi-asserted-by":"crossref","first-page":"e578","DOI":"10.4088\/JCP.13r08905","article-title":"Rapid cycling in bipolar disorder: a systematic review","volume":"75","author":"Carvalho","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0025","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/archpsyc.60.9.914","article-title":"The long-term course of rapid-cycling bipolar disorder","volume":"60","author":"Coryell","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0030","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jpsychires.2007.12.004","article-title":"Rapid-cycling bipolar I disorder: course and treatment outcome of a large sample across Europe","volume":"42","author":"Cruz","year":"2008","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.05.065_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1176\/appi.ajp.2015.15020164","article-title":"An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression","volume":"173","author":"Durgam","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0040","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jad.2015.04.054","article-title":"Antidepressants worsen rapid-cycling course in bipolar depression: a STEP-BD randomized clinical trial","volume":"184","author":"El-Mallakh","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0045","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/bdi.12045","article-title":"A systematic review of the evidence on the treatment of rapid cycling bipolar disorder","volume":"15","author":"Fountoulakis","year":"2013","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0050","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S2215-0366(21)00395-3","article-title":"Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40345-021-00230-8","article-title":"Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study","volume":"9","author":"Higuchi","year":"2021","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0060","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jad.2023.05.065_bb0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/acps.13062","article-title":"A systematic review and meta-analysis of clinical predictors of lithium response in bipolar disorder","volume":"140","author":"Hui","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2023.05.065_bb0070","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2023.05.065_bb0075","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2020.12.005","article-title":"Lurasidone in the long-term treatment of bipolar I depression: a 28-week open label extension study","volume":"281","author":"Ishigooka","year":"2021","journal-title":"J. Affect. Disord."},{"author":"Japanese Pharmaceuticals and Medical Devices Agency (PMDA)","key":"10.1016\/j.jad.2023.05.065_bb0080"},{"author":"Japanese Pharmaceuticals and Medical Devices Agency (PMDA)","key":"10.1016\/j.jad.2023.05.065_bb0085"},{"key":"10.1016\/j.jad.2023.05.065_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpsychires.2020.09.030","article-title":"Clinical features related to rapid cycling and one-year euthymia in bipolar disorder patients: a multicenter treatment survey for bipolar disorder in psychiatric clinics (MUSUBI)","volume":"131","author":"Kato","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.05.065_bb0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/pcn.13137","article-title":"Double-blind, placebo-controlled study of lurasidone monotherapy for the treatment of bipolar I depression","volume":"74","author":"Kato","year":"2020","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.05.065_bb0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jad.2021.07.104","article-title":"Impact of bipolar disorder on health-related quality of life and work productivity: estimates from the national health and wellness survey in Japan","volume":"295","author":"Kato","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0105","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/bdi.12013","article-title":"Lamotrigine as add-on treatment to lithium and divalproex: lessons learned from a double-blind, placebo-controlled trial in rapid-cycling bipolar disorder","volume":"14","author":"Kemp","year":"2012","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0110","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","article-title":"Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study","volume":"33","author":"Ketter","year":"2016","journal-title":"Depress. Anxiety"},{"key":"10.1016\/j.jad.2023.05.065_bb0115","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0120","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4088\/JCP.08m04942gre","article-title":"A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)","volume":"71","author":"McElroy","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0130","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0135","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0140","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/mp.2009.61","article-title":"Bipolar disorder with frequent mood episodes in the national comorbidity survey replication (NCS-R)","volume":"15","author":"Nierenberg","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0145","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/pcn.12894","article-title":"Prevalence of mental disorders and mental health service use in Japan","volume":"73","author":"Nishi","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.05.065_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40345-017-0075-7","article-title":"Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment","volume":"5","author":"Pikalov","year":"2017","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14740338.2017.1379989","article-title":"Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders","volume":"17","author":"Pompili","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2023.05.065_bb0160","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1176\/appi.ajp.2007.05081484","article-title":"The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD","volume":"165","author":"Schneck","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0165","first-page":"22","article-title":"The Mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59 Suppl 20","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1176\/appi.ajp.2017.16101200","article-title":"Adjunctive bright light therapy for bipolar depression: a randomized double-blind placebo-controlled trial","volume":"175","author":"Sit","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1080\/15622970701317265","article-title":"Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies","volume":"9","author":"Suppes","year":"2008","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jad.2009.10.007","article-title":"Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression","volume":"121","author":"Suppes","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0185","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)","volume":"26","author":"Thase","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.05.065_bb0190","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1192\/bjp.bp.112.108357","article-title":"Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression","volume":"201","author":"Tohen","year":"2012","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0195","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000082021","article-title":"The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate","volume":"74","author":"Vieta","year":"2005","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2023.05.065_bb0200","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.4088\/JCP.v65n1019","article-title":"Comparison of rapid-cycling and non-rapid-cycling bipolar I manic patients during treatment with olanzapine: analysis of pooled data","volume":"65","author":"Vieta","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0205","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1399-5618.2007.00479.x","article-title":"Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study","volume":"9","author":"Vieta","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0210","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","article-title":"Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Vos","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2023.05.065_bb0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2023.05.065_bb0220","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.05.065_bb0225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4088\/JCP.08m04995gre","article-title":"A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)","volume":"71","author":"Young","year":"2010","journal-title":"J. Clin. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723007061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723007061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:05:49Z","timestamp":1759032349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723007061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":45,"alternative-id":["S0165032723007061"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.05.065","relation":{},"ISSN":["0165-0327"],"issn-type":[{"type":"print","value":"0165-0327"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of lurasidone in bipolar I depression with and without rapid cycling: A pooled post-hoc analysis of two randomized, placebo-controlled trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.05.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}